Signaling Pathway

p38 MAPK

p38 MAPK

Related Products

PDF File 0.32MB

P38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, andosmotic shock, and are involved in cell differentiation, apoptosis and autophagy. p38 MAP Kinase (MAPK) is the mammalian orthologue of the yeast Hog1p MAP kinase, which participates in a signaling cascade controlling cellular responses to cytokines and stress. Four p38 MAP kinases, p38-α (MAPK14), -β (MAPK11), -γ (MAPK12 / ERK6), and -δ (MAPK13 / SAPK4), have been identified. Similar to the SAPK/JNK pathway, p38 MAP kinase is activated by a variety of cellular stresses including osmotic shock, inflammatory cytokines, lipopolysaccharides (LPS), Ultraviolet light, and growth factors.

p38 MAPK Inhibitors & Modulators (29)

Product Name Catalog No. Brief Description
Acumapimod

HY-16715

Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.

Bakuchiol

HY-N0235

Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.

BMS-582949 hydrochloride

HY-14305A

BMS-582949 hydrochloride is a novel highly selective p38α MAPK inhibitor, inhibits p38α with IC50 of 13 nM.

Chelerythrine Chloride

HY-12048

Chelerythrine is potent, cell-permeable inhibitor of protein kinase C (IC50 = 660 nM); competitive with respect to the phosphate acceptor and non-competitive with respect to ATP.

Dehydrocorydaline chloride

HY-N0674A

Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities.

Doramapimod

HY-10320

Doramapimod (BIRB 796) is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ.

GNE-495

HY-100343

GNE-495 is a potent and Selective MAP4K4 Inhibitor with IC50 of 3.7 nM.

Losmapimod

HY-10402

Losmapimod (GW856553X; SB856553; GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.

LY2228820

HY-13241

LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).

p38 MAPK-IN-1

HY-12839

p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM, shows sustained levels, low clearance and good bioavailability.

Pamapimod

HY-10405

Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor.

PD 169316

HY-10578

PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor (IC50 = 89 nM).

PH-797804

HY-10403

PH-797804 is an ATP-competitive, readily reversible inhibitor of the α isoform of human p38 MAP kinase, exhibiting a Ki = 5.8 nM.

R1487 Hydrochloride

HY-14975

R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α.

SB 202190

HY-10295

SB 202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase with IC50 values of 50 nM and 100 nM for p38α and p38β respectively; also showed slightly weaker activity for BRD4 (Kd=3.4 uM).

SB 203580

HY-10256

SB203580(RWJ 64809) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 uM.

SB 203580 hydrochloride

HY-10256A

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 uM.

SB 239063

HY-11068

SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α).

SB 242235

HY-18306

SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.

SCIO-469

HY-10406

SCIO-469 is a selective ATP-competitive p38 inhibitor with IC50 of 9 nM for p38αin vitro, about 10-fold selectivity for p38α over p38β, and at least 2000-fold selectivity for p38α over an in vitro panel of 20 other kinases, including other MAK kinases.